

CD79A (HM57): sc-53208

BACKGROUND

CD79 (also designated Ig α /Ig β) is a heterodimer composed of α chains, designated CD79A or MB-1, and β chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.

CHROMOSOMAL LOCATION

Genetic locus: CD79A (human) mapping to 19q13.2, Cd79a (mouse) mapping to 7 A3.

SOURCE

CD79A (HM57) is a mouse monoclonal antibody raised against amino acids 202-216 of CD79A of human origin.

PRODUCT

Each vial contains 200 μ g IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

CD79A (HM57) is available conjugated to agarose (sc-53208 AC), 500 μ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-53208 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-53208 PE), fluorescein (sc-53208 FITC), Alexa Fluor[®] 488 (sc-53208 AF488), Alexa Fluor[®] 546 (sc-53208 AF546), Alexa Fluor[®] 594 (sc-53208 AF594) or Alexa Fluor[®] 647 (sc-53208 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor[®] 680 (sc-53208 AF680) or Alexa Fluor[®] 790 (sc-53208 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor[®] is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

CD79A (HM57) is recommended for detection of CD79A of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

CD79A (HM57) is also recommended for detection of CD79A in additional species, including porcine, bovine, canine, chicken, equine, Guinea pig, monkey and rabbit.

Suitable for use as control antibody for CD79A siRNA (h): sc-35025, CD79A siRNA (m): sc-35026, CD79A shRNA Plasmid (h): sc-35025-SH, CD79A shRNA Plasmid (m): sc-35026-SH, CD79A shRNA (h) Lentiviral Particles: sc-35025-V and CD79A shRNA (m) Lentiviral Particles: sc-35026-V.


Molecular Weight of CD79A: 44 kDa.

Positive Controls: Ramos cell lysate: sc-2216, Daudi cell lysate: sc-2415 or GA-10 whole cell lysate: sc-364230.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



CD79A (HM57): sc-53208. Western blot analysis of CD79A expression in Daudi (A), GA-10 (B) and Ramos (C) whole cell lysates.



CD79A (HM57) Alexa Fluor[®] 647: sc-53208 AF647. Direct fluorescent western blot analysis of CD79A expression in Ramos whole cell lysate. Blocked with UltraCruz[®] Blocking Reagent: sc-516214. Cruz Marker[™] Molecular Weight Standards detected with Cruz Marker[™] MW Tag-Alexa Fluor[®] 488: sc-516790.

SELECT PRODUCT CITATIONS

- Han, J.I., et al. 2009. What is your diagnosis? Ascites fluid from an 11-year-old dog with epigastric bulging. *Vet. Clin. Pathol.* 38: 541-544.
- Hiemstra, S., et al. 2015. Beyond parasitism: hepatic lesions in stranded harbor porpoises (*Phocoena phocoena*) without trematode (*Campyla oblonga*) infections. *Vet. Pathol.* 52: 1243-1249.
- Tura, G., et al. 2019. Polymorphic post-transplant lymphoproliferative disorder in a gilt. *Vet. Q.* 39: 136-142.
- Levi, M., et al. 2021. Pathological findings of canine idiopathic pericarditis and pericardial mesotheliomas: correlation with clinical and survival data. *Vet. Sci.* 8: 162.
- Antognoni, M.T., et al. 2021. Non epitheliotropic B-cell lymphoma with plasmablastic differentiation vs. cutaneous plasmacytosis in a 12-years-old Beagle: case presentation and clinical review. *Vet. Sci.* 8: 317.
- Muscattello, L.V., et al. 2022. Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: spatial distribution and score as relevant features of tumor malignancy. *Vet. J.* 283: 105833.
- Parisi, F., et al. 2022. Presence of a mouse mammary tumour virus-like in feline lymphomas: a preliminary study. *Infect. Agent. Cancer* 17: 35.
- Jacinto, J.G.P., et al. 2022. A missense variant in PLP2 in Holstein cattle with X-linked congenital mast cell tumor. *Animals* 12: 2329.
- Mandara, M.T., et al. 2022. Feline lymphoma of the nervous system. Immunophenotype and anatomical patterns in 24 cases. *Front. Vet. Sci.* 9: 959466.

RESEARCH USE

For research use only, not for use in diagnostic procedures.